Interviews

Dr Benjamin George champions accessible cancer care in rural Nebraska, transforming patient support with innovative programs and community engagement.

Dr Benjamin George transforms cancer care in rural Nebraska, ensuring accessible, high-quality treatment for patients in underserved communities.

Benjamin George, MD, combines compassionate oncology care with cutting-edge science, fostering deep patient relationships and offering hope through advanced treatments.

Explore how thalidomide derivatives enhance T-cell responses and combat exhaustion in multiple myeloma therapies for improved patient outcomes.

New research highlights nivolumab AVD as a promising new standard of care for advanced Hodgkin lymphoma, showing improved survival rates and tolerability.

Maen Abdelrahim, MD, PhD, discusses how to manage the dose of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma.

The HER2CLIMB-05 trial reveals tucatinib enhances progression-free survival in HER2-positive metastatic breast cancer, offering new hope for patients.

A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for advanced cancer treatments.

UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, targeting unmet clinical needs.

Sacituzumab govitecan shows improved survival and quality of life in advanced triple-negative breast cancer, outperforming standard chemotherapy in recent trials.

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria as key indicators of patient survival.

Andrew M. Brunner, MD, discusses the most notable outcomes of the phase 2/3 IMerge trial of imetelstat in patients with low-risk myelodysplastic syndrome.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results.

ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.

Matthew Matasar, MD, discusses real-world data on treatment options for diffuse large B-cell lymphoma.

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated DLBCL patients, without rituximab.

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Dr Robert Orlowski highlights strategies to prevent infections in patients with multiple myeloma treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.

Explore the significance of MRD negativity in cancer prognosis and its implications for treatment strategies in community-based practices.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

Researchers explore the safety and efficacy of consolidating cevostamab with BCMA CAR T therapy for relapsed multiple myeloma, highlighting management protocols.

Discover how a remote therapeutic monitoring system enhances patient care and streamlines clinic operations, reducing hospitalizations for hematologic malignancies.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient outcomes.